Dr. Daniel H. Brune, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 241
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Family Medicine Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Saint Francis Medical Center Peoria, IL
- Carle Health Methodist Hospital Peoria, IL
- Carle Health Pekin Hospital Pekin, IL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 241
- Services billed
- 7,281
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,312 | 243 |
| Insertion of needle into vein for collection of blood sample | 570 | 222 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 489 | 56 |
| Established patient office or other outpatient visit, 40-54 minutes | 202 | 138 |
| Aspiration and/or injection of fluid from large joint | 113 | 48 |
| Injection of drug or substance under skin or into muscle | 100 | 11 |
| Urinalysis, manual test | 89 | 49 |
| Urine microalbumin (protein) analysis | 87 | 56 |
| Administration of influenza virus vaccine | 87 | 86 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 85 | 85 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 195 payments worth $4,813 in total to this clinician.
| Teva Pharmaceuticals USA, Inc. | $601 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $453 |
| AbbVie Inc. | $383 |
| Phathom Pharmaceuticals, Inc. | $340 |
| Aimmune Therapeutics, Inc. | $294 |
| Scpharmaceuticals Inc. | $262 |
| Lilly USA, LLC | $261 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $242 |
| Food and Beverage | $4,732 |
|---|---|
| Education | $81.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Jul 29, 2025 | Education in-kind | $81.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $1,316,937 in research payments for these studies, mostly to the institutions running them.
- Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06695130 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A phase 12 randomized doubleblind trial of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults 18 years of age and older
Pfizer Inc. - A phase 3 multicenter parallelgroup openlabel study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion f subunit vaccine when coadministered with herpes zoster subunit vacc…
Pfizer Inc. - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
ModernaTX, Inc. · Completed · NCT05992935 - Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03999996 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT04762680 - A phase 12 randomized study to evaluate the safety tolerability and immunogenicity of a modified rna COVID19 vaccine and a recombinant influenza vaccine administered as a single injection in healthy adults 50 years of…
Pfizer Inc. - Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06118151
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.